About bruker - BRKR
Bruker Corp. engages in the business of developing, manufacturing, and distributing high-performance scientific instruments and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the following segments: Bruker Scientific Instruments (BSI) BioSpin, BSI Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID), BSI NANO, and Bruker Energy and Supercon Technologies (BEST). The BSI BioSpin segment includes life science tools based on magnetic resonance technology. The BSI CALID segment focuses on life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments, and solutions based on infrared and Raman molecular spectroscopy technologies and radiological and nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The BSI NANO segment offers advanced x-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments, analytical tools for electron microscopes and x-ray metrology, defect-detection equipment for semiconductor process control, handheld, portable, and mobile x-ray fluorescence spectrometry instruments, spark optical emission spectroscopy systems, and chip cytometry products and services for targeted spatial proteomics, multi-omics services, and products and services for spatial genomics research. The BEST segment is involved in superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare, and big science research. The company was founded by Emil Bruker and Günther Laukien in 1960 and is headquartered in Billerica, MA.
BRKR At a Glance
Bruker Corp.
40 Manning Road
Billerica, Massachusetts 01821
| Phone | 1-978-663-3660 | | Revenue | 3.44B |
| Industry | Medical Specialties | | Net Income | -8,600,000.00 |
| Sector | Health Technology | | 2025 Sales Growth | 2.082% |
| Fiscal Year-end | 12 / 2026 | | Employees | 11,085 |
|
View SEC Filings
| | | | |
BRKR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.081 |
| Price to Book Ratio | 2.918 |
| Price to Cash Flow Ratio | 53.33 |
| Enterprise Value to EBITDA | 17.881 |
| Enterprise Value to Sales | 2.604 |
| Total Debt to Enterprise Value | 0.228 |
BRKR Efficiency
| Revenue/Employee | 310,013.532 |
| Income Per Employee | -775.823 |
| Receivables Turnover | 4.669 |
| Total Asset Turnover | 0.57 |
BRKR Liquidity
| Current Ratio | 1.73 |
| Quick Ratio | 0.874 |
| Cash Ratio | 0.234 |
BRKR Profitability
| Gross Margin | 47.665 |
| Operating Margin | 8.154 |
| Pretax Margin | 0.64 |
| Net Margin | -0.25 |
| Return on Assets | -0.143 |
| Return on Equity | -0.406 |
| Return on Total Capital | -0.191 |
| Return on Invested Capital | -0.205 |
BRKR Capital Structure
| Total Debt to Total Equity | 83.163 |
| Total Debt to Total Capital | 45.404 |
| Total Debt to Total Assets | 32.731 |
| Long-Term Debt to Equity | 81.054 |
| Long-Term Debt to Total Capital | 44.253 |